Regression of pulmonary metastatic disease associated with intralesional bcg therapy of intracutaneous melanoma metastases

Mastrangelo, Michael J.; Bellet, Robert E.; Berkelhammer, Jane; Clark, Wallace H.

doi:10.1002/1097-0142(197510)36:4<1305::aid-cncr2820360417>3.0.co;2-#

Cited by 66 publications

(29 citation statements)

References 4 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 90% of intradermal lesions injected with BCG regress. Uninjected lesions also regressed in up to 20% of patients, showing a systemic and local immune response [25,35,36].…”

Section: Local and Regional Therapymentioning

confidence: 69%

Evaluation of Immunotherapy in the Treatment of Melanoma

Faries¹

2006

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

“…Approximately 90% of intradermal lesions injected with BCG regress. Uninjected lesions also regressed in up to 20% of patients, showing a systemic and local immune response [25,35,36].…”

Section: Local and Regional Therapymentioning

confidence: 69%

Evaluation of Immunotherapy in the Treatment of Melanoma

Faries¹

2006

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

“…Intralesional therapy for metastases from melanoma was first systematically evaluated in the 1970s with Bacillus Calmette Guerin (BCG) which was first reported to produce remission in injected lesions and also distant metastases [64]. An immune-mediated systemic response was hypothesized to be the basis behind the occasional systemic response, but randomized trials of BCG have failed to confirm a significant clinical benefit [65].…”

Section: Potential For Intralesional Therapy For Melanomamentioning

confidence: 99%

Progression of cutaneous melanoma: implications for treatment

Leong

Mihm

Murphy

et al. 2012

Clin Exp Metastasis

View full text Add to dashboard Cite

The survival rates of melanoma, like any type of cancer, become worse with advancing stage. Spectrum theory is most consistent with the progression of melanoma from the primary site to the in-transit locations, regional or sentinel lymph nodes and beyond to the distant sites. Therefore, early diagnosis and surgical treatment before its spread is the most effective treatment. Recently, new approaches have revolutionized the diagnosis and treatment of melanoma. Genomic profiling and sequencing will form the basis for molecular taxonomy for more accurate subgrouping of melanoma patients in the future. New insights of molecular mechanisms of metastasis are summarized in this review article. Sentinel lymph node biopsy has become a standard of care for staging primary melanoma without the need for a more morbid complete regional lymph node dissection. With recent developments in molecular biology and genomics, novel molecular targeted therapy is being developed through clinical trials.

show abstract

“…17,18 Similar frequencies of response in injected lesions were demonstrated and regression of even distant metastatic disease was observed in the setting of injection of superficial metastases. 19 It is fascinating, in the era of ipilimumab, to note that the regression of a lung metastasis after BCG injection into skin metastases was observed after initial progression of the distant site. The time course of this delayed response parallels almost exactly that observed in delayed ipilimumab responses that are seen frequently with current checkpoint blockade.…”

Section: The Modern Era Beginsmentioning

confidence: 99%

Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology

Faries

2016

Crit Rev Oncog

View full text Add to dashboard Cite

The last few years have yielded exciting developments in immunotherapy for cancer. The promise of cancer immunotherapy has been well known for many years, but had generally produced limited or inconsistent benefit to patients. Intralesional therapies, which are in fact one of the oldest forms of immunotherapy, are also demonstrating benefits in the modern age. This review discusses the origins of intralesional immunotherapy and its underlying rationale. It also discusses the reemergence of this mode of therapy into the modern era, which is where Donald L. Morton, subject of this edition of the journal, plays a major role. The review also discusses current areas of investigation. Given the intuitive advantages of this strategy and the demonstrated, expanding areas of clinical responses, it is likely that intralesional immunotherapy will remain a useful component of cancer treatment into the future.

show abstract

Regression of pulmonary metastatic disease associated with intralesional bcg therapy of intracutaneous melanoma metastases

Cited by 66 publications

References 4 publications

Evaluation of Immunotherapy in the Treatment of Melanoma

Evaluation of Immunotherapy in the Treatment of Melanoma

Progression of cutaneous melanoma: implications for treatment

Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology

Contact Info

Product

Resources

About